No B shares were repurchased and a total of 5,500 treasury shares were sold to Novo Nordisk employees in relation to existing incentive programmes during the third quarter of 2001.
22,500,000 B shares of the company's holding of own shares were cancelled during the third quarter as announced on 24 August 2001.
This announcement is pursuant to Section 204.33, Treasury Stock Changes, of the New York Stock Exchange Listed Company Manual.
This announcement is pursuant to Section 204.33, Treasury Stock Changes, of the New York Stock Exchange Listed Company Manual.
Novo Nordisk is a focused healthcare company and the world leader in diabetes care. In addition, Novo Nordisk has a leading position within areas such as coagulation disorders, growth disorders and hormone replacement therapy. Novo Nordisk manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical profession and society. With headquarters in Denmark, Novo Nordisk employs approximately 15,000 people in 68 countries and markets its products in 179 countries. Novo Nordisk's B shares are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed on the New York Stock Exchange under the symbol 'NVO'.
For further company information visit www.novonordisk.com
For further information please contact:
Elin K Hansen
Tlf. (direkte): 4442 3450
Tlf. (direkte): 4442 3450
Investorer:
Uden for Nordamerika:
Peter Haahr
Tlf. (direkte): 4442 1207
Peter Haahr
Tlf. (direkte): 4442 1207
Palle Holm Olesen
Tlf. (direkte): 4442 6175
Tlf. (direkte): 4442 6175
Stock Exchange Announcement No 17 / 2001